Keryx Biopharma (KERX) Plans Presentation of Ferric Citrate Phase 3 Data in IDA at ASN Annual Meeting
- Wall St. rises amid robust GDP data, mixed earnings
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that researchers will present new data from a pivotal Phase 3 study of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent chronic kidney disease (CKD). Researchers will also present post-marketing analysis detailing real-world use of Auryxia® (ferric citrate) as a treatment for hyperphosphatemia in people with CKD on dialysis. The data will be presented in five poster presentations at the 2016 American Society of Nephrology (ASN) Annual Meeting being held November 15 - 20, 2016, in Chicago.
Auryxia® is currently indicated in the U.S. for the control of serum phosphorus levels in patients with CKD on dialysis. Abstracts of the five presentations are accessible on ASN’s website at https://www.asn-online.org/education/kidneyweek/archives/.
Four abstracts related to IDA will be presented together in a poster session on Thursday, November 17, 2016 from 10:00 a.m. to 12:00 p.m. Central Time (CST).
Abstract Number: 2200Presenter: Steven Fishbane, M.D.Title: Effects of ferric citrate in adults with non-dialysis dependent chronic kidney disease and iron deficiency anemia: Phase 3 Clinical Trial
Abstract Number: 3705Presenter: Glenn Chertow, M.D.Title: Hemoglobin response to ferric citrate in subjects with non-dialysis dependent chronic kidney disease and iron deficiency anemia: Data from a Phase 3 clinical trial
Abstract Number: 3429Presenter: Geoffrey Block, M.D.Title: Effects of ferric citrate on parameters of mineral and bone metabolism in patients with non-dialysis dependent chronic kidney disease treated for iron deficiency anemia
Abstract Number: 3937Presenter: Pablo Pergola, M.D.Title: Predictors of hemoglobin response to ferric citrate in patients with non-dialysis dependent chronic kidney disease and iron deficiency anemia
One abstract related to the treatment of hyperphosphatemia with Auryxia in the dialysis setting will be presented in a poster presentation on Friday, November 18, 2016 from 10:00 a.m. to 12:00 p.m. CST.
Abstract Number: 2598Presenter: Pablo Pergola, M.D.Title: The effect of ferric citrate (Auryxia) on serum phosphate control in dialysis patients: Real-world data
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sientra (SIEN) Enters Prelim. Settlement of All Outstanding Class Action Litigation
- Noble Corp (NE) Will Eliminate Quarterly Dividend Payments
- Aytu BioScience (AYTU) Prices $8.6M Common Stock, Warrants Offering
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!